Sermorelin and GHRH-T are both growth hormone-releasing hormone (GHRH) analogs, but they differ in length and stability. Sermorelin is the minimal functional GHRH fragment, while GHRH-T is a stabilized full-length analog.
| Property | Sermorelin | GHRH-T |
|---|---|---|
| Category | GHRH(1-29) analog (shortest fully active GHRH fragment) | Stabilized full-length GHRH(1-44) analog (trans-3-hexenoyl modification) |
| Mechanism of Action | Binds GHRH receptor on pituitary somatotrophs; stimulates pulsatile GH secretion in model systems | Binds GHRH receptor; the N-terminal hexenoyl group confers resistance to DPP-4 degradation, extending activity |
| Molecular Weight | ~3,358 Da (29 amino acids) | ~5,136 Da (44 amino acids + hexenoyl moiety) |
| Research Focus | GHRH receptor signaling and GH pulsatility assays | GHRH receptor signaling and peptide stability (DPP-4 resistance) studies |
| Receptor Target | GHRH receptor | GHRH receptor |
| Half-Life | ~10-20 minutes | ~26-38 minutes |
Sermorelin and GHRH-T engage the same GHRH receptor but represent different design choices. Sermorelin strips GHRH to its minimal active fragment, producing a short-acting tool for studying GH pulsatility. GHRH-T preserves the full-length sequence and armors it against DPP-4 degradation, yielding a longer-acting analog. Both preserve the natural pulsatile pattern of GH release, distinguishing GHRH analogs from direct GH.
Both are GHRH receptor agonists. Sermorelin is the minimal GHRH(1-29) fragment with a ~10-20 minute half-life. GHRH-T is a full-length GHRH(1-44) analog stabilized against DPP-4 degradation, with a longer half-life.
Disclaimer: All compounds referenced on this page are sold for research and laboratory use only. The comparisons presented are based on published scientific literature and are intended for educational and informational purposes. This content does not constitute medical advice. Researchers should consult primary literature and applicable regulations before designing study protocols.